Mizuho initiated coverage of Charles River Laboratories with a Neutral rating and $235 price target. The analyst is positive on the long-term growth outlook for the company and industry, but believes near-term visibility is limited due to the macroeconomic and funding environment coupled with the potential for increased competitive pricing pressure. As a result, the firm prefers to remain on the sidelines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River initiated with a Buy at Goldman Sachs
- Charles River announces launch of VCG initiative with Sanofi
- Charles River participates in a conference call with JPMorgan
- Charles River price target lowered to $228 from $260 at TD Cowen
- Charles River price target lowered to $270 from $282 at Baird